R. Buhl (Mainz, Germany), A. Morice (Cottingham, United Kingdom)
Systemic inflammation is enhanced by acute hyperglycaemia and suppressed by insulin in COPD
J. Archer, E. Baker (London, United Kingdom)
|  |
Risks of diabetes mellitus and hyperglycaemic adverse events in patients with COPD taking inhaled corticosteroids
S. Rennard, P. O‘Byrne, F. Radner, S. Peterson, E. Ekholm, B. Lindberg, D. Sin (Omaha, United States Of America; Hamilton, Vancouver, Canada; Lund, Sweden)
| |
The relationship between acidic & non acidic gastro esophageal reflux disease (GERD) and asthma
W. Tarsin, I. Alshamli, E. Alabbasi, E. Naas, M. Soussi (Tripoli, Libyan Arab Jamahiriya)
| |
Effects of pantoperazole on pulmonary function tests of chronic obstructive pulmonary disease patients, with and without gastro esophageal reflux
F. Malek, R. Ghorbani, F. Yaghobi (Semnan, Islamic Republic Of Iran)
| |
The relationship between obesity and distal airways
G. Marin, N. Molinari, I. Vachier, P. Godard, P. Chanez, A. S. Gamez, A. Bourdin (Montpellier, Marseille, France)
| |
Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization
T. Pertseva, K. Gashynova (Dnipropetrovsk, Ukraine)
| |
A comparative study to evaluate the effects of salmetrol/fluticasone and formoterol/budesonide combinations on lung functions and sleep quality in asthma
M. Gupta, D. Chaudhry, P. Jindal (Rohtak, India)
| |
ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients
A. D‘Urzo, B. Make, E. Kerwin, L. Rekeda, E. Garcia Gil, C. Caracta, B. Maurer (Toronto, Canada; Denver, Medford, Jersey City, United States Of America; Barcelona, Spain)
| |
Differences in adherence to inhaled steroid medication in COPD
M. Brusse-Keizer, P. van der Valk, J. van der Palen (Enschede, Netherlands)
| |
The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice
M. L. Zaremba, K. Elliott, A. Redford, S. Ali, N. Shah, S. Reddy (Port Huron, United States Of America)
| |
The effect of L-arginine on ciliary function in primary ciliary dyskinesia (PCD)
R. Hirst, N. Martin, M. Fadaee-Shohada, C. Smith, G. Williams, A. Rutman, C. O‘Callaghan (Leicester, United Kingdom)
| |
Formoterol, but not indacaterol, induces transient hypoxemia in severe COPD
R. W. Dal Negro, P. Pescatori, C. Micheletto, S. Tognella (Bussolengo, Italy)
| |
An audit on emergency oxygen administration and safety issues
R. K. Yadavilli, N. Anwar, B. Bradley (Bolton, United Kingdom)
| |
No difference observed in the risk of malignancy in patients exposed to omalizumab compared with controls
R. Buhl, C. Fernandez Vidaurre, M. Blogg, J. Zhu, M. D. Eisner, J. Canvin, W. Busse (Mainz, Germany; East Hanover, South San Francisco, Madison, United States Of America; Horsham, United Kingdom)
|  |
The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease
E. D. Bateman, D. Singh, P. W. Jones, A. Agusti, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Cape Town, South Africa; Manchester, London, United Kingdom; Barcelona, Spain; , United States Of America)
| |
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
S. F. Weinstein, M. Noonan, W. E. Berger, H. Staudinger (Huntington Beach, Portland, Mission Viejo, Kenilworth, United States Of America)
| |
Fluticasone propionate/formoterol fumarate combination therapy has comparable efficacy to its individual components administered concurrently
A. Bodzenta-Lukaszyk, J. A. van Noord, W. G. Schröder-Babo, K. McAulay, T. McIver (Bialystok, Poland; Heerlen, Netherlands; Gelnhausen, Germany; Cambridge, United Kingdom)
| |
Body mass index, disease control and airway inflammation in asthmatic patients
R. Pisi, M. Aiello, P. Tzani, E. Marangio, D. Olivieri, A. Chetta (Parma, Italy)
| |
How does obesity correlate with severe asthma?
D. Gibeon, W. Banya, H. Markus, R. Suzanne, P. Bhavsar, K. F. Chung, A. Menzies-Gow (London, United Kingdom)
| |
Effects on adrenal function of a new combination of fluticasone propionate/formoterol fumarate administered to asthmatic patients and healthy subjects
M. Tamm, K. Kaiser, B. Grothe, M. Lomax (Basel, Muttenz, Switzerland; Cambridge, United Kingdom)
| |